MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.

被引：0
|
作者：
Bekaii-Saab, Tanios S.
Van Cutsem, Eric
Tabernero, Josep
Siena, Salvatore
Yoshino, Takayuki
Nakamura, Yoshiaki
Raghav, Kanwal Pratap Singh
Cercek, Andrea
Heinemann, Volker
Adelberg, David E.
Ward, James Edward
Yang, Shan
Andre, Thierry
Strickler, John H.
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Univ Leuven, Leuven, Belgium
[4] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain
[5] Grande Osped Metropolitano Niguarda, Milan, Italy
[6] Univ Milan, Milan, Italy
[7] Natl Canc Ctr Hosp Japan East, Kashiwa, Chiba, Japan
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[10] Univ Munich, Munich, Germany
[11] Merck & Co Inc, Kenilworth, NJ USA
[12] Seagen Inc, Bothell, WA USA
[13] Sorbonne Univ, Paris, France
[14] Hop St Antoine, INSERM Instabil Microsatellites & Canc, Paris, France
[15] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS261
引用
收藏
页码：TPS261 / TPS261
页数：1
相关论文
共 50 条
  • [41] Effectiveness of Trastuzumab in First-Line HER2+Metastatic Breast Cancer After Failure in Adjuvant Setting: A Controlled Cohort Study
    Negri, Eva
    Zambelli, Alberto
    Franchi, Matteo
    Rossi, Marta
    Bonifazi, Martina
    Corrao, Giovanni
    Moja, Lorenzo
    Zocchetti, Carlo
    La Vecchia, Carlo
    ONCOLOGIST, 2014, 19 (12): : 1209 - 1215
  • [42] Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
    Yamazaki, K.
    Nagase, M.
    Tamagawa, H.
    Ueda, S.
    Tamura, T.
    Murata, K.
    Nakajima, T. Eguchi
    Baba, E.
    Tsuda, M.
    Moriwaki, T.
    Esaki, T.
    Tsuji, Y.
    Muro, K.
    Taira, K.
    Denda, T.
    Funai, S.
    Shinozaki, K.
    Yamashita, H.
    Sugimoto, N.
    Okuno, T.
    Nishina, T.
    Umeki, M.
    Kurimoto, T.
    Takayama, T.
    Tsuji, A.
    Yoshida, M.
    Hosokawa, A.
    Shibata, Y.
    Suyama, K.
    Okabe, M.
    Suzuki, K.
    Seki, N.
    Kawakami, K.
    Sato, M.
    Fujikawa, K.
    Hirashima, T.
    Shimura, T.
    Taku, K.
    Otsuji, T.
    Tamura, F.
    Shinozaki, E.
    Nakashima, K.
    Hara, H.
    Tsushima, T.
    Ando, M.
    Morita, S.
    Boku, N.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1539 - 1546
  • [43] Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
    Zhou, F.
    Wang, W.
    Xia, L.
    Dai, J.
    Wu, H.
    Yang, L.
    Gong, J.
    Chen, X.
    Xiong, Z.
    Liang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S439 - S439
  • [44] Treatment patterns following first-line pertuzumab plus trastuzumab in patients with HER2+metastatic breast cancer in the United States.
    Mehta, Sandhya
    Pavilack, Melissa
    Xie, Jipan
    Ionescu-Ittu, Raluca
    Nie, Xiaoyu
    Lei, Yin
    Kwong, Jackie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
    Nishina, Tomohiro
    Takano, Yoshinao
    Denda, Tadamichi
    Yasui, Hisateru
    Takeda, Koji
    Ura, Takashi
    Esaki, Taito
    Okuyama, Yusuke
    Kondo, Ken
    Takahashi, Yasuo
    Sugiyama, Yasuyuki
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1080 - 1086
  • [46] Effectiveness of trastuzumab in first-line HER2+metastatic breast cancer after failure in adjuvant setting: A controlled cohort study.
    Negri, Eva
    Zambelli, Alberto
    Franchi, Matteo
    Rossi, Marta
    Bonifazi, Martina
    Corrao, Giovanni
    Zambon, Antonella
    Moja, Lorenzo
    Zocchetti, Carlo
    La Vecchia, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
    Hiroshi, Tamagawa
    Kentaro, Yamazaki
    Koichi, Suyama
    Michio, Okabe
    Kazuya, Suzuki
    Nobuhiko, Seki
    Kentaro, Kawakami
    Mikio, Sato
    Yasuo, Takahashi
    Tomonori, Hirashima
    Masahide, Ebi
    Keisei, Taku
    Toshio, Otsuji
    Fumio, Tamura
    Eiji, Shinozaki
    Koji, Nakashima
    Kensei, Yamaguchi
    Masahiko, Ando
    Satoshi, Morita
    Narikazu, Boku
    Ichinosuke, Hyodo
    ANNALS OF ONCOLOGY, 2014, 25
  • [48] Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT
    Tabernero, J.
    Prager, G.
    Stintzing, S.
    Lenz, H. J.
    Nygren, H. P.
    Papadimitriou, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Tabernero, J.
    Strickler, J.
    Nakamura, Y.
    Shitara, K.
    Janjigian, Y.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H.
    Yoshino, T.
    Siena, S.
    Garrido-Mayor, J.
    Ubowski, M.
    Xie, D.
    Marshall, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S305 - S306
  • [50] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Strickler, J.
    Nakamura, Y.
    Shitara, K.
    Catenacci, D.
    Janjigian, Y.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H.
    Lee, J.
    Van Cutsem, E.
    Chung, H.
    Tabernero, J.
    Yoshino, T.
    Siena, S.
    Garrido-Mayor, J.
    Palanca-Wessels, M.
    Xie, D.
    Marshall, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S159 - S159
12345